Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders

Haematologica

Volumn 97, Issue 8, 2012, Pages 1272-1277

  Ross, Fiona M ^a   Avet Loiseau, Hervé ^b   Ameye, Geneviève ^c   Gutiérrez, Norma C ^d   Liebisch, Peter ^e   O'Connor, Sheila ^f   Dalva, Klara ^g   Fabris, Sonia ^h   Testi, Adele M ⁱ   Jarosova, Marie ^j   Hodkinson, Clare ^k   Collin, Anna ^l   Kerndrup, Gitte ^m   Kuglik, Petr ⁿ   Ladon, Dariusz ^o   Bernasconi, Paolo ^p   Maes, Brigitte ^q   Zemanova, Zuzana ^r   Michalova, Kyra ^r   Michau, Lucienne ^s   Neben, Kai ^t   Hermansen, N Emil U ^u   Rack, Katrina ^v   Rocci, Alberto ^w   Protheroe, Rebecca ^a   Chiecchio, Laura ^a   Poirel, Hélène A ^c   Sonneveld, Pieter ^x   Nyegaard, Mette ^y   Johnsen, Hans E ^y   more..

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f St James's Institute of Oncology   (United Kingdom)

^g ANKARA UNIVERSITY   (Turkey)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^k ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m LILLEBAELT HOSPITAL   (Denmark)

ⁿ MASARYK UNIVERSITY   (Czech Republic)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^q VIRGA JESSE HOSPITAL   (Belgium)

^r CHARLES UNIVERSITY   (Czech Republic)

^s UNIVERSITY OF LEUVEN   (Belgium)

^t UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^u Rigshospitalet   (Denmark)

^v INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^w UNIVERSITY OF TURIN   (Italy)

^x ERASMUS MEDICAL CENTER   (Netherlands)

^y AALBORG UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Cytogenetic; Interphase FISH; Myeloma; Recommendation

Indexed keywords

FLUORESCENT DYE;

ARTICLE; EUROPE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MULTIPLE MYELOMA; PLASMA CELL; PRACTICE GUIDELINE; QUALITY CONTROL; WORKSHOP;

HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; PRACTICE GUIDELINES AS TOPIC;

EID: 84864758817     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.056176     Document Type: Article

References (21)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):3-21.
2. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 1996;93(24): 13931-6.
3. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88(2):674-81.
4. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20(40):5611-22.
5. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-87.
6. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194:96-104.
7. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Dávila R, González-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562-7.
8. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of 9multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558.
9. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1999;24(1):9-15.
10. Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, Grosbois B, Bataille R. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. Blood. 1999; 94(8):2583-9.
11. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, Jäger U, Fiegl M, Geissler K, Ludwig H, Huber H. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86(10): 3915-21.
12. Gutiérrez NC, Camps J, Hernández JM, García JL, Prat E, González MB, Miró R, San Miguel JF. Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance. Hematol J. 2003;4(1):67-70.
13. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100(4):1417-24.
14. Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21(1):143-50.
15. Stewart AK, Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn. 2007;7(4):453-9.
16. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571-96.
17. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol. 2007;20(4):625-35.
18. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12):2210-21.
19. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18): 4701-5.
20. Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007;136(4):615-23.
21. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on cosegregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2): 349-55.